[Skip to Content]
[Skip to Content Landing]

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

Educational Objective
To identify the key insights or developments described in this article

Bispecific antibodies (bsAb) targeting novel antigens are a promising class of therapeutics for relapsed refractory multiple myeloma (RRMM).1,2 Although hypogammaglobulinemia is expected due to plasma cell depletion,35 little is known regarding the degree of humoral immunodeficiency and infectious complications with bsAb. We report on the kinetics of humoral deficiency among patients with RRMM treated with bsAb, the infectious complications, and response to COVID-19 immunization.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: September 9, 2022.

Published: October 28, 2022. doi:10.1001/jamanetworkopen.2022.38961

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Hammons LR et al. JAMA Network Open.

Corresponding Author: Meera Mohan, MD, MS, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 (memohan@mcw.edu).

Author Contributions: Drs Hammons and Mohan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Dhakal, Chhabra, D’Souza, Mohan.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Szabo, Dhakal, D’Souza, Mohan.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Hammons, Szabo.

Administrative, technical, or material support: Janardan.

Supervision: Dhakal, Mohan.

Conflict of Interest Disclosures: Dr Dhakal reported consulting for Janssen Pharmaceuticals and Karyopharm Therapeutics Inc and serving on the advisory boards of Sanofi, Amgen Inc, Natera, and Arcellx, Inc, outside the submitted work. Dr D’Souza reported serving on clinical trial advisory boards for Janssen Pharmaceuticals and Prothena Corporation PLC, performing clinical trials for Teneobio, Inc, Regeneron Pharmaceuticals, Inc, and Caelum, and serving on the advisory boards of Bristol-Myers Squibb Company, Caelum, and Pfizer Inc outside the submitted work. Dr Mohan reported receiving institutional research funding from Takeda Pharmaceutical Company Limited, Novartis AG, Celgene/Bristol-Myers Squibb Company, and GSK PLC outside the submitted work. No other disclosures were reported.

Disclaimer: All information and materials in the manuscript are original.

Meeting Presentation: These findings were presented in part at the Annual Meeting of the American Society of Clinical Oncology; June 4, 2022; Chicago, Illinois.

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close